Watchlist Price Alert

Alcon Inc. (ALC)

NYSE: ALC · Real-Time Price · USD

89.29

0.27 (0.30%)

At close: Jul 02, 2025, 3:59 PM

89.48

0.21%

After-hours: Jul 02, 2025, 04:44 PM EDT

0.30% (1D)

Bid	85.81
Market Cap	44.16B
Revenue (ttm)	9.94B
Net Income (ttm)	1.12B
EPS (ttm)	2.25
PE Ratio (ttm)	39.68
Forward PE	24
Analyst	Buy

Ask	89.5
Volume	895,664
Avg. Volume (20D)	1,710,857
Open	88.55
Previous Close	89.02
Day's Range	88.55 - 89.50
52-Week Range	80.48 - 101.10
Beta	0.70

About ALC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ALC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ALC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Alcon Inc. is scheduled to release its earnings on Aug 19, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-6.45%

Alcon shares are trading lower after the company r... Unlock content with Pro Subscription

3 months ago

+6%

Alcon shares are trading higher. The company acquired majority interest in Aurion Biotech.

News

1 hour ago · zacks.com

Is it Apt to Retain Alcon Stock in Your Portfolio for Now?

ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.

6 days ago · businesswire.com

Alcon Canada Earns Global Recognition as a Top Employer

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Can...

1 week ago · businesswire.com

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intrao...

4 weeks ago · businesswire.com

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...

1 month ago · zacks.com

Alcon Stock Rises Following the FDA Approval of TRYPTYR

FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.

1 month ago · reuters.com

US FDA approves Alcon's new dry-eye drug

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

1 month ago · businesswire.com

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.

1 month ago · seekingalpha.com

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

Alcon Inc. (NYSE:ALC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stone...